Shots: Shots:

• Mogrify to receive upfront- development- regulatory and commercial milestones and will be responsible for the discovery & optimization of the cell conversion technology from iPSCs or ESCs to regulatory T cells
• Sangamo to get exclusive rights to use Mogrify’s technology to develop Tregs from iPSCs/ESCs. The company anticipates utilizing its ZFP technology & capabilities in transforming the Tregs into “off-the-shelf” allogeneic CAR-Treg cell therapies and further develop them for inflammatory and autoimmune diseases
• The collaboration will accelerate the development of scalable and accessible CAR-Treg cell therapies to deliver potential treatments for inflammatory and autoimmune diseases more rapidly

Click here ­to­ read full press release/ article | Ref: Sangamo | Image: Sangamo- Mogrify